ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Efficacy of venetoclax combined with hypomethylating agents in the treatment of patients newly diagnosed with core binding factor acute myeloid leukemia].
S Y Han, X Y Xu, M Zhou, H X Zhou, D P Wu, Y Han
Abstract readEnglish Abstract
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
S Y HanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
X Y XuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
M ZhouNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
H X ZhouNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
D P WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Y HanNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Funding
grants from the Jiangsu Province of China BE2021645National Natural Science Foundation of China 8230005, 820701043, 81873432Natural Science Foundation of Boxi Cultivation Program of the First Affiliated Hospital of Soochow University BXQN2024032Suzhou Science and Education Health Youth Project QNXM2024009
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Bridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAdultAntineoplastic Combined Chemotherapy ProtocolsCore Binding FactorsFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeBridged Bicyclo Compounds, HeterocyclicCore Binding FactorsSulfonamidesvenetoclaxCore-binding factor leukemiaHypomethylating agentsVenetoclax
Identifiers
PMID41087182
PMCPMC12541477
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390